creso

Creso Pharma (ASX:CPH | OTC:COPHF) has announced plans to acquire psychedelic company Halucenex Life Sciences.

Halucenex is focused on researching, developing and licensing novel psychedelic molecules for the global pharmaceutical markets and is currently progressing clinical trials to research the efficacy of psilocybin used in psychedelic-assisted psychotherapy to treat and alleviate Treatment Resistant Depression and other mental illnesses.

Acquisition marks the first 100%-owned psychedelic medicines company on the Australian Stock Exchange.

Recent News

Get the Creso
Investor’s Kit now.

Compounds

Market Cap

ASX: CPH

Focus